Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344762 | 1.00 | CTSK (0.48) | CTSKCTSSCYP2D6PPARAPPARG | |
| SCHEMBL2018992 | 1.00 | CTSK (0.48) | CTSKCTSSCYP2D6PPARAPPARG | |
| Hydrochloric Acid SCHEMBL25223716 | 0.98 | CTSK (0.47) | CTSKCTSSCYP2D6PPARAPPARG | |
| Hydrochloric Acid SCHEMBL25223717 | 0.98 | CTSK (0.47) | CTSKCTSSCYP2D6PPARAPPARG | |
| SCHEMBL3682214 | 0.91 | CYP2D6 (0.55) | CTSKCTSSCYP2D6PPARAPPARG | |
| SCHEMBL343679 | 0.91 | CYP2D6 (0.55) | CTSKCTSSCYP2D6PPARAPPARG | |
| SCHEMBL343678 | 0.91 | CYP2D6 (0.55) | CTSKCTSSCYP2D6PPARAPPARG | |
| SCHEMBL31181958 | 0.88 | REN (0.48) | CTSKCTSSCYP2D6CTSLCTSB | |
| SCHEMBL24313584 | 0.86 | CYP1A2 (0.48) | CTSKCTSSCYP2D6CTSLCTSB | |
| SCHEMBL1688833 | 0.86 | CYP1A2 (0.48) | CTSKCTSSCYP2D6CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101798292-A | Method for preparing novel Bc1-2 protein inhibitor derived from ABT-263 | WUXI HOWFOND BIOPHARMA CO LTD | 2010-08-11 | — | — | CN | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2024-02-08 | — | — | US | disclosed |
| CN-101024671-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-08-29 | — | — | CN | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| CN-1974596-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-06-06 | — | — | CN | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-0505467-A1 | PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES | Astra Pharmaceuticals Limited (GB) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991008737-A2 | PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES | FISONS PLC (GB) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885CYP2D6 2731/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | CTSK 3949/4885CTSS 3675/4885CYP2D6 4123/4885 |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CTSK 1284/4885CTSS 2183/4885CYP2D6 1003/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885CYP2D6 2731/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | CTSK 2167/4885CTSS 2726/4885CYP2D6 93/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | CTSK 1492/4885CTSS 1158/4885CYP2D6 4241/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CTSK 3397/4885CTSS 2756/4885CYP2D6 695/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | CTSK 1138/4885CTSS 958/4885CYP2D6 477/4885 |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | CTSK 2369/4885CTSS 3965/4885CYP2D6 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.